Presentation is loading. Please wait.

Presentation is loading. Please wait.

The ONgoing Telmisartan Alone and in

Published byCarina Skoglund Modified over 5 years ago

Similar presentations

Presentation on theme: "The ONgoing Telmisartan Alone and in"— Presentation transcript:

1 The ONgoing Telmisartan Alone and in
ONTARGET The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial Salim Yusuf, Koon K. Teo, Janice Pogue, Leanne Dyal, and Ingrid Copland, Population Health Research Institute and Investigators Yusuf, et al. N ENGL J MED.358;15: 1

2 Change in BP (mmHg) ONTARGET Ramipril Telmisartan Combination Systolic
-6.0 -6.9 -8.4 Diastolic -4.6 -5.2 Yusuf, et al. N ENGL J MED.358;15: 2

3 Time to Permanent Discontinuation
ONTARGET Time to Permanent Discontinuation of Study Medication NO. at Risk Telmisartan 8542 7954 7384 6909 6478 Ramipril 8576 7796 7165 6681 6254 Years of Follow-up Cumulative Hazard Rates Yusuf, et al. N ENGL J MED.358;15:

4 Reasons for Permanently Stopping Study Medications
ONTARGET Reasons for Permanently Stopping Study Medications Ram N=8576 Tel N=8542 Tel vs. Ram RR P Hypotension 149 229 1.54 0.0001 Syncope 15 19 1.27 0.4850 Cough 360 93 0.26 <0.0001 Diarrhea 12 1.59 0.20 Angioedema 25 10 0.40 0.0115 Renal Impairment 60 68 1.14 0.46 Any Discontinuation 2099 1962 0.94 0.02 Yusuf, et al. N ENGL J MED.358;15:

5 Time to Primary Outcome
ONTARGET Time to Primary Outcome Telmisartan Cumulative Hazard Rates Ramipril Years of Follow-up NO. at Risk 8542 8176 7778 7420 7051 Telmisartan 8576 8214 7832 7473 7095 Ramipril Yusuf, et al. N ENGL J MED.358;15:

6 Primary Outcome & HOPE Primary Outcome
ONTARGET Primary Outcome & HOPE Primary Outcome Ram Tel Tel vs Ram N (%) RR (95% CI) P (non-inf) N 8576 8542 Primary Outcome CV Death, MI, Stroke, CHF Hosp 1412 (16.46%) 1423 (16.66%) 1.01 ( ) 0.0038 (Adjusted for SBP) 1.02 ( ) 0.0055 HOPE Primary Outcome CV Death, MI, Stroke 1210 (14.11%) 1190 (13.93%) 0.99 ( ) 0.0009 0.0012 Yusuf, et al. N ENGL J MED.358;15: 6

7 Time to Primary Outcome
ONTARGET Time to Primary Outcome Ramipril Cumulative Hazard Rates Tel.&Ram. Years of Follow-up NO. at Risk 8576 8214 7832 7473 7095 Ramipril 8502 8134 7740 7377 7023 Tel.&Ram. Yusuf, et al. N ENGL J MED.358;15: 7 7

8 Reasons for Permanently Stopping Study Medications
ONTARGET Reasons for Permanently Stopping Study Medications Ram N=8576 Ram + Tel N=8502 Ram + Tel vs. Ram RR P Hypotension 149 406 2.75 <0.0001 Syncope 15 29 1.95 0.032 Cough 360 392 1.10 0.1885 Diarrhea 12 39 3.28 0.0001 Angioedema 25 18 0.73 0.30 Renal Impairment 60 94 1.58 0.0050 Any Discontinuation 2099 2495 1.20 Yusuf, et al. N ENGL J MED.358;15:

Download ppt "The ONgoing Telmisartan Alone and in"

Similar presentations

Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.

Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.
Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.

Statin Landmark Trials Across the Spectrum of Risk: Secondary CV Prevention.
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;

Atorvastatin in Type 2 diabetics on dialysis: 4D Study 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF;
Valsartan Antihypertensive Long-Term Use Evaluation Results

Valsartan Antihypertensive Long-Term Use Evaluation Results
The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
Daily Dilemmas in Hypertension Management. Objectives Review the impact of hypertension on society Review the impact of hypertension on society Review.

Daily Dilemmas in Hypertension Management. Objectives Review the impact of hypertension on society Review the impact of hypertension on society Review.
Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,

Is It the Achieved Blood Pressure or Specific Medications that Make a Difference in Outcome, or Is the Question Moot? William C. Cushman, MD Professor,
Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.

Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345:851-860, 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.

Duality of interests S.Yusuf has received fees for lecturing and research grants from Cadilla Pharma, as well as from 6 other pharma companies that produce.
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,

TRANSCEND: Telmisartan Randomized AssesmeNt Study in aCE iNtolerant Subjects with Cardiovascular Disease ONTARGET / TRANSCEND Investigators Koon K. Teo,
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.

The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.

Similar presentations

Ads by Google